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licenses/by/4.0/).Abstract Introduction: Delays in cancer diagnosis arose from the commencement of non-
pharmaceutical interventions (NPI) introduced in the UK in March 2020 in response to the
COVID-19 pandemic. Our earlier work predicted this will lead to approximately 3620 avoid-
able deaths for four major tumour types (breast, bowel, lung, and oesophageal cancer) in the
next 5 years. Here, using national population-based modelling, we estimate the health and eco-
nomic losses resulting from these avoidable cancer deaths. We also compare these with the
impact of an equivalent number of COVID-19 deaths to understand the welfare consequences
of the different health conditions.
Methods: We estimate health losses using quality-adjusted life years (QALYs) and lost eco-
nomic productivity using the human capital (HC) approach. The analysis uses linked English
National Health Service (NHS) cancer registration and hospital administrative datasets for
patients aged 15e84 years, diagnosed with breast, colorectal, and oesophageal cancer between
1st Jan to 31st Dec 2010, with follow-up data until 31st Dec 2014, and diagnosed with lungol of Hygiene and Tropical Medicine Department of Health Services Research and Policy, London, WC1H
.ac.uk (A. Aggarwal).
ors.
et al., Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19
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pandemic: A national population-basedcancer between 1st Jan to 31st Dec 31 2012, with follow-up data until 31st Dec 2015. Produc-
tivity losses are based on the estimation of excess additional deaths due to cancer at 1, 3 and 5
years for the four cancer types, which were derived from a previous analysis using this dataset.
A total of 500 random samples drawn from the total number of COVID-19 deaths reported by
the Office for National Statistics, stratified by gender, were used to estimate productivity losses
for an equivalent number of deaths (n Z 3620) due to SARS-CoV-2 infection.
Results: We collected data for 32,583 patients with breast cancer, 24,975 with colorectal can-
cer, 6744 with oesophageal cancer, and 29,305 with lung cancer. We estimate that across the
four site-specific cancers combined in England alone, additional excess cancer deaths would
amount to a loss of 32,700 QALYs (95% CI 31,300-34,100) and productivity losses of
£103.8million GBP (73.2e132.2) in the next five years. For breast cancer, we estimate a loss
of 4100 QALYS (3900e4400) and productivity losses of £23.2 m (18.2e28.6); for colorectal
cancer, 15,000 QALYS (14,100e16,000) lost and productivity losses of £35.7 m (22.4e48.7);
for lung cancer 10,900 QALYS (9,900e11,700) lost and productivity losses of £38.3 m (14.0
e59.9) for lung cancer; and for oesophageal cancer, 2700 QALYS (2300e3,100) lost and pro-
ductivity losses of £6.6 m (e6 to e17.6). In comparison, the equivalent number of COVID-19
deaths caused approximately 21,450 QALYs lost, as well as productivity losses amounting to
£76.4 m (73.5e79.2).
Conclusion: Premature cancer deaths resulting from diagnostic delays during the first wave of
the COVID-19 pandemic in the UK will result in significant economic losses. On a per-capita
basis, this impact is, in fact, greater than that of deaths directly attributable to COVID-19.
These results emphasise the importance of robust evaluation of the trade-offs of the wider
health, welfare and economic effects of NPI to support both resource allocation and the prior-
itisation of time-critical health services directly impacted in a pandemic, such as cancer care.
ª 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The introduction of non-pharmaceutical interventions
(NPIs) designed to curb the transmission of COVID-19,
including national lockdowns, and other physical
distancing measures, has had a significant impact on
cancer pathways from presentation through to
diagnosis and treatment.
In the UK, following the first wave of the
pandemic, up to 3 million men and women did not
receive screening investigations due to suspension of
these services, fewer patients were referred with sus-
pected cancers [1], and 3.2 million fewer investigations
(e.g., colonoscopy, cystoscopy, gastroscopy, CT scans,
MRI between March and July 2020) were performed
due to cancellation or deferral [2,3]. This decrease in
referrals and diagnostic investigation implies an
eventual later diagnosis with more advanced-stage
cancer, which will have a direct impact on long term
prognosis [4,5]. As well as diagnostic pathways, it has
also become rapidly apparent that treatment de-
lays [6], especially for cancer surgery, were also
occurring [7,8].
Presently, in the UK, we find ourselves amid a second
pandemic wave, which started in November 2020. Once
again, many diagnostic investigations have been de-
ferred or delayed (particularly routine investigations,
which account for 40% of all cancer diagnoses [9]),
cancer surgery cancelled, and reductions have beenet al., Economic impact of avoida
modelling study in England, UK, Eobserved in the number of patients presenting with
suspected cancers [10]. These delays in the cancer
pathway will undoubtedly have consequences on pre-
mature mortality [11].
A major question is whether any of these effects could
have been mitigated, particularly with respect to
resource allocation and prioritisation of non-COVID
related health services for time-critical diseases, if the
government had accurately weighed up the direct eco-
nomic and health impacts of NPI across the spectrum of
health care services.
In this respect, estimating the economic consequences
of changes in disease burden is crucial for understanding
these welfare trade-offs. Specifically, whether the costs
of implementing different types of NPI are justified
when considering both their expected benefits and their
wider impacts on other health conditions.
Similar evaluations unrelated to the pandemic have
been undertaken in the context of cancer [12] to quantify
the economic impact of premature mortality from can-
cer in different international regions. The outputs have
been used to directly influence policy, particularly pri-
oritisation and financial investment into a different
component of the cancer care pathway to reduce the
number of avoidable deaths [13].
In this study, we model the economic impacts of
diagnostic delay during the COVID-19 pandemic using
excess mortality estimates derived from the study by
Maringe et al., [14] published in July 2020, whichble cancer deaths caused by diagnostic delay during the COVID-19
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bowel, lung and oesophagus), delays in diagnosis due to
NPI during the first pandemic wave would lead to
approximately 3620 avoidable deaths and 60,000 life
years lost within 5 years of diagnosis.
We use a human capital approach to estimate pro-
ductivity losses from excess cancer deaths due to diag-
nostic delay from NPIs. We also compare estimates
from excess cancer deaths with the same number of
COVID-19 deaths to understand the health and eco-





Information on all adults with non-small cell lung can-
cer (NSCLC, ICD-10: C33, C34), cancers of the colon
(ICD-10: C18) and rectum (ICD-10: C19), cancers of the
oesophagus and gastro-oesophageal junction (ICD-10:
C15, C16.0) and women with breast cancer (ICD-10:
C50) were obtained from the National Cancer Regis-
tration Service (NCRS). The pre-pandemic cohort in-
cludes patients diagnosed in 2010 for cancers of the
breast, colon, rectum and oesophagus and 2012 for
patients diagnosed with NSCLC in England. We
restricted the analyses to patients aged 15e84 years at
diagnosis.
2.1.2. COVID-19 patients
COVID-19 deaths are deaths that occurred in England
and Wales up to 6th October 2020, inclusive with any
mention of COVID-19 on the death certificate, by
gender and 5-year age groups, from the Office for Na-
tional Statistics (ONS) [15]. National life tables are from
the ONS, based on 2016e2018 data [16].
2.2. Approach
We value health and economic losses using two estab-
lished Indicators: (i) quality-adjusted life years (QALYs)
and (ii) the human capital (HC), which measures the lost
productivity associated with death. QALYs are calcu-
lated by estimating the years of life remaining for each
patient and weighting each year with a quality-of-life
score. For example, a year lived in perfect health is
worth 1 QALY [17].
The HC approach estimates the productivity losses
incurred by sick or deceased workers assuming it is
irreplaceable. In keeping with the literature, we assume
average personal income as a proxy for the value of lost
productivity; we calculated the total value of produc-
tivity loss as the cumulative sum of personal income lost
over the duration of illness (morbidity) and the number
of years lost due to premature death (mortality),Please cite this article as: Gheorghe A et al., Economic impact of avoida
pandemic: A national population-based modelling study in England, UK, Eassuming not all individuals are employed (age-sex-
specific employment rates) and a retirement age of 66
[18].
Average age-sex-specific gross earnings are sourced
from the 2019 (provisional) results of the Annual Survey
of Hours and Earnings (ASHE) [19], and age-sex-spe-
cific employment rates are sourced from the 2019 results
of the Labour Force Survey (LFS) [20], both published
by the ONS. A proportional adjustment is made to
isolate the earnings of 65e66-year olds in the 65e69
years age group based on the mid-2019 population
estimates in the UK by discrete years [21].
Projected excess deaths due to delays in diagnosis for
breast, lung, colorectal and oesophageal cancer, by 5-
year age bands (e.g. 65e69), at 1, 3 and 5 years after
diagnosis are based on scenario C of Maringe et al.,
which reallocated patients from non-urgent pathways to
2-week wait and emergency referral pathways in pro-
portions designed to reflect the real-time and future
anticipated changes in access to diagnostic services in
the 12 months following commencement of the first
wave lockdown 16th March 2020 [14]. The median age
for each age band considered is, e.g. 22 years for the
20e24 years age group.
2.3. Statistical analyses
2.3.1. QALYS estimation
Based on age-sex average crude probabilities of death
calculated at 1, 3 and 5 years post-diagnosis, we assume
that cancer deaths at 1-year post-diagnosis occur in
2021, at 3-years in 2023 and at 5-years in 2025. The
calendar year when deaths occur is important to know
from an economic perspective because cause and health
losses occurring further into the future are valued less
(discounted) relative to those occurring in or closer to
the present. Productivity losses and QALYs lost from
2021 onwards were discounted at 3.5% per annum back
to the reference year (2019).
We estimate QALYs lost based on the age distribu-
tion at death due to cancer and apply age-specific UK
quality of life norms, discounted to obtain their 2019
value [17]. QALYs lost due to the effect of the first
lockdown are estimated by taking the difference between
the QALYs estimated for the deaths due to cancer
observed pre-pandemic and those estimated following
the effects of the first lockdown on diagnostic patterns.
2.3.2. Productivity losses estimation
We multiply the individual crude probabilities of cancer
death, estimated at 1, 3 and 5 years after diagnosis, with
the economic costs of a death calculated using the HC
approach, stratified by 5-year age group and gender. We
sum these quantities to obtain the economic value of the
cancer deaths across the entire sampled cohort, repre-
senting the calendar period 16th March 2020 to 15th
March 2021. By taking the difference between thisble cancer deaths caused by diagnostic delay during the COVID-19
uropean Journal of Cancer, https://doi.org/10.1016/j.ejca.2021.04.019
A. Gheorghe et al. / European Journal of Cancer xxx (xxxx) xxx4quantity and the total economic value of deaths in the
pre-pandemic cohort, and averaging across 500 boot-
strapped datasets, we obtain the average (and 95% CI,
percentile method) economic costs of cancer deaths in
addition to those to be expected pre-pandemic, i.e. the
excess productivity losses due to additional excess can-
cer deaths.
We compared the economic burden of additional
excess deaths in the cancer population with that of an
equal estimated number of COVID-19 deaths (nZ 3620
deaths), based on 500 random samples drawn from the
total number of COVID-19 deaths up to October 2020
(stratified by age). COVID-19 deaths were converted in
QALYs using the method and calculator developed by
Briggs, which also adjusts for multiple comorbidities
[22]. The productivity and QALYs losses associated with
COVID-19 deaths were estimated by multiplying deaths
with the age-sex adjusted HC multiplier described
above.
3. Results
We analysed data on 32,583 patients with breast cancer,
24,975 with colorectal cancer, 29,305 with lung cancer,
and 6744 with oesophageal cancer. Patients were all
diagnosed in England. Patients were aged 15e84 years
and the mean age at diagnosis was 60$5 years (Standard
Deviation (SD) 12$6) for breast cancer, 68$5 years
(10$7) for colorectal cancer, 68$5 years (10$3) for
oesophageal cancer, and 69$8 years (9$3) for lung can-
cer. 10,441 (41$8%) of 24,975 patients diagnosed with
colorectal cancer, 13,211 (45$1%) of 29,305 diagnosed
with lung cancer, and 1894 (28$1%) of 6744 diagnosed
with oesophageal cancer were women. Table 1 presents
three measures of the estimated impact following
COVID-19-related delay in diagnosis.
3.1. Cancer deaths
The number of additional cancer deaths resulting from
the diagnostic delay due to the COVID 19 pandemic was
1646 (1566e1729 deaths) for colorectal cancer up to
Year 5, 1290 (1281e1299 deaths) for lung cancer, 344
for breast cancer (326e361 deaths), and 335 (325e345
deaths) additional deaths for oesophageal cancer (Table
1).
3.2. COVID-19 deaths
Up to 06 October 2020, there had been 53,863 deaths in
total. The age distribution of death occurrences where
COVID-19 was mentioned on the death certificate
(Appendix 1) is based on cumulative deaths up to and
including week 41 (09 October 2021). 61% of deaths
occurred among those aged over 80 years and a further
28% among those aged 65e79 years. 45% of COVID-19
deaths occurred in women. Estimates for QALYS lostPlease cite this article as: Gheorghe A et al., Economic impact of avoida
pandemic: A national population-based modelling study in England, UK, Eand productivity losses were based on 3620 COVID-19
deaths.3.3. QALYS
We estimate that the additional cancer deaths due to
diagnostic delay during the COVID-19 pandemic would
result in 2700 QALYs lost for oesophageal cancer, 4100
QALYs lost for breast cancer, 10,900 QALYs lost for
lung cancer and 15,000 QALYs lost for colorectal can-
cer. Across the four cancer sites combined, additional
excess deaths would amount to approximately 32,700
QALYs lost (Table 1).3.4. Productivity losses
Under the human capital approach, across these four
cancers, additional productivity losses would amount to
103.8 (95% confidence interval 73.2 to 132.2) million
GBP. Lung and colorectal cancers account for the
largest share of productivity losses (38.3 and 35.7
million respectively), followed by breast cancer (23.2
million) and oesophageal cancer (6.6 million) (Table 1).
Fig. 1 and Fig. 2 demonstrate that for breast and
colorectal cancers, excess losses in QALYs and pro-
ductivity accumulate gradually from 2021 to 2025 at
comparable and reasonably constant rates. For lung and
oesophageal cancer, however, the burden is frontloaded
within a year since diagnosis and losses are incurred by
the end of 2021. This is due to differences across the four
cancers in the cumulative probability of death over time
since diagnosis translating in different temporal profiles
of the excess burden (see Fig. 3).
The uncertainty around the point estimates of pro-
ductivity losses calculated under the human capital
approach is high, particularly for lung and oesophageal
cancers. Oesophageal cancer accounts for the least share
of the excess burdenamong the four cancer types across all
scenarios andmetrics, andproductivity losses are unlikely
to be statistically different from pre-pandemic quantities.3.5. Indirect economic impact of COVID-19 versus cancer
deaths
COVID-19 deaths were estimated to result in the loss of
21,450 QALYs, as well as 76.4 (73.5e79.2) million
worth of lost economic output under the human capital
approach. Additional excess deaths due to the four
selected cancers are estimated to result in an additional
11,300 (9900 to 12,700) more QALYs lost compared to
an equivalent number of COVID-19 deaths (Fig. 2).
Differences in excess productivity losses amount to 27.6
(0.8 to 53.3) million GBP.ble cancer deaths caused by diagnostic delay during the COVID-19
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Fig. 1. Cumulative QALY losses associated with additional excess cancer deaths by cancer site and year.
Table 1
QALY and productivity losses associated with additional excess cancer deaths by cancer site.
Cancer site Approach Pre-pandemic
(observed)
First wave pandemic
(estimated with 95% CI)
Differences in observed and
estimated QALY and productivity
losses due to additional
excess cancer deaths
Breast Deaths 3564 3908 (3891e3926) 344 (326e361)
QALYs (thousands) 37.1 41.3 (40.1e41.6) 4.1 (3.9e4.4)
Productivity losses (GBP million)
Human capital approach 267.0 290.2 (285.2e295.6) 23.2 (18.2e28.6)
Colorectal Deaths 9416 11,062 (10,982e11,145) 1646 (1566e1729)
QALYs (thousands) 80.9 95.9 (95.0e96.8) 15.0 (14.1e16.0)
Productivity losses (GBP million)
Human capital approach 410.1 445.8 (432.6e458.8) 35.7 (22.4e48.7)
Lung Deaths 25,800 27,090 (27,081e27,099) 1290 (1281e1299)
QALYs (thousands) 220.1 231.0 (230.1e231.8) 10.9 (9.9e11.7)
Productivity losses (GBP million)
Human capital approach 805.3 843.6 (819.3e865.2) 38.3 (14.0e59.9)
Oesophagus Deaths 5713 6048 (6038e6047) 335 (325e345)
QALYs (thousands) 50.5 53.2 (52.8e53.7) 2.7 (2.3e3.1)
Productivity losses (GBP million)
Human capital approach 195.5 202.1 (191.4e213.1) 6.6 (4.0e17.6)
Total cancer Deaths 44,493 48,109 (48,020e48,200) 3615 (3526e3706)
QALYs (thousands) 388.7 421.4 (419.9e422.8) 32.7 (31.3e34.1)
Productivity losses (GBP million)
Human capital approach 1677.9 1781.7 (1751.1e-1810.1) 103.8 (73.2e132.2)
Abbreviations: QALY e quality-adjusted life-years discounted to 2019 value.
Notes: 95% confidence intervals obtained from 500 bootstraps, percentile method. Totals may not add up due to rounding.
A. Gheorghe et al. / European Journal of Cancer xxx (xxxx) xxx 54. Discussion
Our findings indicate that the projected impact of excess
deaths due to delays in cancer diagnosis across England
will lead to significant health and economic losses. The
predicted excess deaths for four major tumour typesPlease cite this article as: Gheorghe A et al., Economic impact of avoida
pandemic: A national population-based modelling study in England, UK, Ecombined (bowel, breast, lung and oesophagus) translate
into an approximate loss of 32,700 quality-adjusted life
years and productivity losses of between 73 and 132
million GBP over 5 years.
Colorectal cancer accounts for the largest produc-
tivity losses among the four cancers; from a third ofble cancer deaths caused by diagnostic delay during the COVID-19
uropean Journal of Cancer, https://doi.org/10.1016/j.ejca.2021.04.019
Fig. 3. Productivity and QALY losses associated with additional excess cancer deaths and an equal number of COVID-19 deaths stratified
by age.
Fig. 2. Cumulative productivity losses associated with additional excess cancer deaths by cancer site and year.
A. Gheorghe et al. / European Journal of Cancer xxx (xxxx) xxx6excess productivity losses to just under half the total
excess losses in QALYs. In addition, notable differences
are evident in the magnitude and rate of accumulation
of losses across the different cancers. Whilst delays duePlease cite this article as: Gheorghe A et al., Economic impact of avoida
pandemic: A national population-based modelling study in England, UK, Eto diagnosis were expected to result in a similar number
of additional cancer deaths for breast and oesophageal
cancer, the difference in age profile (breast cancer with a
mean age of 60.5 years versus oesophageal cancer with able cancer deaths caused by diagnostic delay during the COVID-19
uropean Journal of Cancer, https://doi.org/10.1016/j.ejca.2021.04.019
A. Gheorghe et al. / European Journal of Cancer xxx (xxxx) xxx 7mean age of 68.5 years) and prognosis of the two can-
cers result in higher estimated productivity losses and
QALYs losses for breast cancer. In addition, we find
that the burden of additional excess cancer deaths is
likely to be higher than that of a comparable number of
COVID-19 deaths due to the younger age profile of
deaths from cancer [23].
The results complement those from an Australian
Study that estimated the healthcare costs associated
with stage migration (from Stage I to Stage II) of four
cancers (breast, colorectal, lung and melanoma) due to
3 month and 6-month delays in diagnosis during the
pandemic [24]. A 3-month delay is predicted to result
in $12 million AUD excess health care costs over 5
years, and a 6-month delay $46 million AUD. Two
other international studies have highlighted the
increased risk of financial toxicity that cancer patients
face during the COVID-19 pandemic due to rising
unemployment levels and economic recession, meaning
patients have to increasingly pay out of pocket due to
loss of employment-based insurance or may forgo life-
saving treatments to support their families financially
[25,26].
Our results demonstrate that NPI such as national
lockdowns will have substantial health and economic
impacts and does call into question the “protect the
NHS” messaging that was used to support NPI, as the
NHS faces up to the prospect of managing the legacy
(e.g. cancer diagnostic and treatment backlogs, signifi-
cant waiting lists (>1e2 years) for benign health con-
ditions) in the context of stagnating health budgets over
the next few years. If these trade-offs had been consid-
ered more accurately and explicitly from the outset, it
would have undoubtedly helped to support the mitiga-
tion strategies needed to avert this silent epidemic.
It could be argued that comprehensive decision
frameworks and accompanying mathematical models
that incorporate wider health, social and economic
consequences were not available at the time when de-
cisions were made. For example, it was only in mid-
November 2020 that Imperial College released a UK-
focused combined epidemiological and economic model
that accounted for interdependencies between economic
sectors [27].
However, the UK government’s ONS report pub-
lished in July 2020, which was designed to estimate the
indirect impacts of NPI on other health conditions,
significantly under-estimated the true impact on cancer
services of diagnostic delay (3500 QALYs lost across
eighteen cancers) [28]. A more accurate and integrated
assessment would have supported better trade-off deci-
sion-making around the extent of NPIs and the alloca-
tion of resources to mitigate the indirect impact of NPI
on non-COVID healthcare pathways such as cancer.
It should be noted that our estimates are very con-
servative with regards to the health and economic
impact. Recent data [5] suggest that the drop in expectedPlease cite this article as: Gheorghe A et al., Economic impact of avoida
pandemic: A national population-based modelling study in England, UK, Ecancer diagnoses based on yearly estimates is far greater
than the estimates we have made in this paper [14]. For
example, for bowel cancer between April to
October 2020, over 3500 fewer people had been diag-
nosed and treated for colorectal cancer in England than
would have been expected [7]. Likewise, urgent referrals
for suspected lung cancer were 35% lower between
MarcheNovember 2020 compared with the same time
period in 2019, which equates to around 17,800 fewer
referrals [29]. Many of these patients may never present
or when they do, will present with advanced-
stage disease.
The economic losses are predicted to be 103 million
GBP in England alone. Therefore, extrapolating across
the whole of the UK that has a population of 66 million,
we estimate 121 million GBP in economic losses. When
considering the impact of the second wave and the
present national lockdown, which has persisted for over
three months since December 2020 and is not expected
to be fully scaled back till June 2021, it is not unrea-
sonable to expect this figure to have doubled for just
these four tumour types.
The estimates of productivity losses also do not
consider the downstream impact of treatment delay,
particularly of elective cancer surgery and changes to
treatment doses and schedules. Even a 4-week delay in
cancer treatment (surgery, chemotherapy and radio-
therapy) increases the risk of mortality by approxi-
mately 10% [30], with a 3-month delay in cancer surgery
alone across all incident solid tumours estimated to
incur 4755 excess deaths [31].
Looking widely across Europe, substantial delays in
diagnosis are a consistent finding. For example, in Paris
alone, during the first wave (March to May 2020), new
cancer presentations declined by 30% in comparison to
the 2018/19 average [32]. Likewise, in the Netherlands,
national-level data between Feb and April 2020 during
their first wave demonstrated a persistent nearly 30%
decline in the diagnosis of new cancers, which had not
recovered by the end of the study [33].
Our results are significant for two major policy do-
mains going forward. The first is that subsequent waves
of COVID continue to add to overall system delays and
excess death for cancer and other diseases [7]. The
longer it takes to address these backlogs, the greater the
clinical, economic and welfare costs will be, adding to an
already indebted society. Greater investment to ensure
resilience in the health system over the next few years
will be a necessity, given clear evidence of the impact of
previous economic downturns on rising mortality rates
from diseases such as cancer [34]. The second policy
issue relates to the importance of evidenced-based trade-
off considerations around NPI. Our analysis demon-
strates the importance of accurately quantifying the in-
direct effects of NPI on critical non-pandemic related
health care services such as cancer care that require an
integrated response from public health to hospital-basedble cancer deaths caused by diagnostic delay during the COVID-19
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behaviour and their perception of risk.
A strength of this study is the use of linked national
administrative health records of actual patients diag-
nosed and treated in the NHS for the four tumour types.
While the data is retrospective, it still provides a robust
template for modelling the economic productivity losses
due to premature deaths from cancer, as it is represen-
tative of the age and sex distribution of patients diag-
nosed with these cancers in the NHS, which is essential
when modelling economic losses.
In terms of limitations, our results are based on the
predicted number of additional deaths within five years,
for four cancer sites in England alone and not based on
observed additional excess deaths, which will take a
year(s) to show on official figures. However, it is
imperative that further research establishes whether this
has been the case. In addition, there is uncertainty in the
productivity losses calculated, especially for oesophagus
and lung cancer deaths. However, this uncertainty is
unlikely to alter the essence of our findings.
Extrapolating our estimates across all cancers using
this model would require a separate empirical analysis
for each individual tumour. For example, the impact of
diagnostic delay in prostate cancer on additional excess
deaths is likely to be much smaller compared to the
impact on head and neck and gastric cancers. Equally,
extrapolating these economic losses across Europe is
prone to significant bias as the predicted excess death is
dependent on the burden, stage distribution and survival
from these cancers, which we know is variable across
different health systems in Europe [35]. In addition, the
type and extent of NPIs introduced across Europe was
variable and would again impact the number of addi-
tional excess deaths.
We do not directly consider the additional health care
costs associated with an increasing proportion of pa-
tients presenting with late-stage disease [24]. As well as
greater morbidity, it has been shown that Stage III/IV
disease is more costly to manage than patients present-
ing with Stage I and II disease [36]. When clearer esti-
mates for stage migration are available, it will be
possible to model these impacts in the future, which will
be important when considering how cancer budgets need
to adapt to the increased proportion of patients pre-
senting with advanced-stage disease. Finally, we capture
only productivity losses due to premature mortality and
not morbidity-related costs, and indirect effects on pa-
tient carers and disrupted family lives that will also in-
crease the economic burden on countries [37].
From a wider health system perspective, cancers
represent approximately 35% of all incident deaths in
the UK and just over a third of all deaths from non-
communicable diseases. As such, the four considered
cancers amount to 10e15% of all NCD-related deaths
[38]. While extrapolations are difficult at this point
(within and beyond cancer) without additional data,Please cite this article as: Gheorghe A et al., Economic impact of avoida
pandemic: A national population-based modelling study in England, UK, Eeven with simplifying assumptions, one can reasonably
conclude that service disruptions in chronic disease
pathways, e.g. cardiac and renal disease other than those
considered here [39], are likely to have broader societal
impacts many times over what we estimated in this
study, spread over the following years.
5. Conclusions
In summary, we estimate that the additional excess
cancer deaths for breast, colorectal, lung, and oeso-
phageal cancer due to diagnostic delay in England
resulting from NPIs, will translate into productivity
losses of £104million over 5 years. The results are so-
bering when one considers we only focus on four
tumour types and do not consider either the impact of
treatment delays or NPIs that were initiated during the
2nd pandemic wave. There is an urgent need for in-
vestment to manage the rising cancer diagnostic and
treatment backlog. In addition, the results emphasise the
importance of accurate and transparent modelling of
direct and indirect effects of NPIs on the wider health
system prior to their introduction to support both
resource allocation and prioritisation of time-critical
health care services such as cancer care.
Author contributions
AA, AG, CM, KC, RS, MM and BR conceived and
designed the study. AG and CM analysed the data. AG,
CM, AA, RS, BR were involved in data interpretation.
AG and AA wrote the first draft of the paper. AG
produced the manuscript figures and tables. AG, CM,
JS, AP, KC, BR, RS and AA were involved in reviewing
and editing drafts of the paper and approving the
manuscript.
Conflict of interest statement
The authors declare that they have no known
competing financial interests or personal relationships
that could have appeared to influence the work reported
in this paper.
Acknowledgements
The study was funded UK Research and Innovation
Economic and Social Research Council GCRF. ES/
P010962/1. This work uses data provided by patients
and collected by the NHS as part of their care and
support. AG acknowledges funding from the Research
Councils United Kingdom through the Research for
Health in Conflict in the Middle East and North Africa
(ES/P010962/1) and is a member of AG is a member of
the MRC Centre for Global Infectious Disease Analysis
(MRC GIDA), jointly funded by the United Kingdomble cancer deaths caused by diagnostic delay during the COVID-19
uropean Journal of Cancer, https://doi.org/10.1016/j.ejca.2021.04.019
A. Gheorghe et al. / European Journal of Cancer xxx (xxxx) xxx 9Medical Research Council (MRC) (MR/RO15600/1).
CM and BR are funded through the Cancer Research
UK Population Research Committee Funding Scheme:
Cancer Research UK Population Research Committee -
Programme Award (C7923/A20987 and C7923/A29018).
RS is funded through the UK Research and Innovation
GCRF RESEARCH FOR HEALTH IN CONFLICT
(R4HC-MENA) ES/P010962/1. AA is supported by a
National Institute for Health Research (NIHR)
Advanced Fellowship (NIHR300599). JS is supported
by the National Institute for Health Research (NIHR)
Biomedical Research Centre based at Guy’s and St
Thomas’ NHS Foundation Trust and King’s College
London (IS-BRC-1215-20006), and the Cancer
Research UK King’s Health Partners Centre at King’s
College London (C604/A25135). The views expressed in
this publication are those of the author(s) and not
necessarily those of the NHS, the National Institute for
Health Research or the Department of Health and So-
cial Care.
Appendix A. Supplementary data
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ejca.2021.04.019.References
[1] Gathani T, Clayton G, E M, Horgan K. The COVID-19
pandemic and impact on breast cancer diagnoses: what happened
in England in the first half of 2020. Br J Canc 2020;124:710e2.
[2] Greenwood E, Swanton C. Consequences of COVID-19 for
cancer care d a CRUK perspective. Nat Rev Clin Oncol 2021;18:
3e4.
[3] Rutter M, Brookes M, Lee T, Rogers P, Sharp L. Impact of the
COVID-19 pandemic on UK endoscopic activity and cancer
detection: a National Endoscopy Database Analysis. Gut 2020;
70:537e43.
[4] McCormack V, Aggarwal A. Early cancer diagnosis: reaching
targets across whole populations amidst setbacks. Br J Canc 2021;
124:1181e2.
[5] Purushotham ARG, Haire K, Dodkins J, Harvey-Jones E, Han L,
Twinn C, et al. The impact of national non-pharmaceutical in-
terventions (“lockdowns”) on the presentation of cancer patients.
Ecancermedicalscience 2021;15:1180e7.
[6] Spencer K, Jones CM, Girdler R, et al. The impact of the
COVID-19 pandemic on radiotherapy services in England, UK: a
population-based study. Lancet Oncol 2021;22:309e20.
[7] Morris EJA, Goldacre R, Spata E, et al. Impact of the COVID-19
pandemic on the detection and management of colorectal cancer
in England: a population-based study. Lancet Gastroenterol
Hepatol 2021;6(3):199e208.
[8] Boyle J, Kuryba A, Blake H, et al. The impact of the first peak of
the COVID-19 pandemic on colorectal services in England and
Wales; a national survey. Colorectal Dis 2021:1e12.
[9] Elliss-Brookes L, McPhail S, Ives A, et al. Routes to diagnosis for
cancer - determining the patient journey using multiple routine
data sets. Br J Canc 2012;107(8):1220e6.
[10] Donnelly L. Cancer surgery delays are biggest concern as services
struglle with COVID, say NHS Chief. The Telegraph 2021:4.Please cite this article as: Gheorghe A et al., Economic impact of avoida
pandemic: A national population-based modelling study in England, UK, E[11] Hanna TP, King WD, Thibodeau S, et al. Mortality due to cancer
treatment delay: systematic review and meta-analysis. BMJ 2020;
371:m4087.
[12] Hilhorst S, Lockey A. Cancer Costs: a ‘ripple effect’ analysis of
cancer’s wider impact. Demos; 2019.
[13] Rodin D, Burger EA, Atun R, et al. Scale-up of radiotherapy for
cervical cancer in the era of human papillomavirus vaccination in
low-income and middle-income countries: a model-based analysis
of need and economic impact. Lancet Oncol 2019;20(7):915e23.
[14] Maringe C, Spicer J, Morris M, et al. The impact of the COVID-
19 pandemic on cancer deaths due to delays in diagnosis in En-
gland, UK: a national, population-based, modelling study. Lancet
Oncol 2020;21(8):1023e34.
[15] Office for National Statistics. Deaths registered weekly in England
and Wales, provisional. June 2020. https://www.ons.gov.uk/
peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/
datasets/weeklyprovisionalfiguresondeathsregisteredineng
landandwales. [Accessed 16 June 2020].
[16] Office for National Statistics. National life tables, UK. 2019.
https://www.ons.gov.uk/peoplepopulationandcommunity/births
deathsandmarriages/lifeexpectancies/datasets/nationallifeta
blesunitedkingdomreferencetables. [Accessed 16 June 2020].
[17] Janssen B, Szende A. Population norms for the EQ-5D. Self-re-
ported population health: an international perspective based on
EQ-5D. Netherlands: Springer; 2014.
[18] BBC News. State pension age hits 66 and set to rise further. BBC;
2020. October 06, 2020, https://www.bbc.co.uk/news/business-
54421662. [Accessed 28 October 2020].
[19] Office for National Statistics. Earnings and hours worked, age
group. Table 6. ASHE; 2019. https://www.ons.gov.uk/employme
ntandlabourmarket/peopleinwork/earningsandworkinghours/
datasets/agegroupashetable6. [Accessed 14 October 2020].
[20] Office for National Statistics. Employment, unemployment and
economic inactivity for people aged 16 years and over and aged






[21] Estimates of the population for the UK, England and Wales,
Scotland and Northern Ireland. 2020. https://www.ons.gov.uk/
peoplepopulationandcommunity/populationandmigration/
populationestimates/datasets/populationestimatesforukengland
andwalesscotlandandnorthernireland. [Accessed 27 November
2020].
[22] Briggs A. Moving beyond ‘lives-saved’ from COVID-19. Avalon
Health Economics; 2020. https://avalonecon.com/moving-
beyond-lives-saved-from-covid-19/. [Accessed 16 June 2020].
[23] Cancer mortality by age. 2019. https://www.cancerresearchuk.org/
health-professional/cancer-statistics/mortality/age#heading-Zero.
[Accessed 15 December 2020].
[24] Degeling K, Baxter NN, Emery J, et al. An inverse stage-shift
model to estimate the excess mortality and health economic
impact of delayed access to cancer services due to the COVID-19
pandemic. Asia Pac J Clin Oncol 2021;1:1e9.
[25] Baddour K, Kudrick LD, Neopaney A, et al. Potential impact of
the COVID-19 pandemic on financial toxicity in cancer survivors.
Head Neck 2020;42(6):1332e8.
[26] Kong YC, Sakti VV, Sullivan R, Bhoo-Pathy N. Cancer and
COVID-19: economic impact on households in Southeast Asia.
Ecancermedicalscience 2020;14:1134.
[27] Haw D, Christen P, Forchini G, et al. DAEDALUS: an
economic-epidemiological model to optimize economic activity
while containing the SARS-CoV-2 pandemic. London: Imperial
College London; 2020.
[28] Office for National Statistics. Direct and indirect impacts of
COVID-19 on excess deaths and morbidity: executive summary.ble cancer deaths caused by diagnostic delay during the COVID-19
uropean Journal of Cancer, https://doi.org/10.1016/j.ejca.2021.04.019




[29] Cancer Research UK. Recognition and referral of suspected lung
cancer in the UK during the COVID-19 pandemic. 2021.
[30] Hanna T, King W, Thibodeau S, et al. Mortality due to cancer
treatment delay: systematic review and meta-analysis. Br Med J
2020:371.
[31] Sud A, Jones M, Broggio J, et al. Collateral damage: the impact
on outcomes from cancer surgery of the COVID-19 pandemic.
Ann Oncol 2020;31(8):1065e74.
[32] Kempf E, Lame G, Layese R, et al. New cancer cases at the time
of the sars-cov2 pandemic and related public health policies. Eur J
Canc 2021;150:260e7.
[33] Din Mohamed AG, Visser O, Verhoeven RHA, et al. Fewer
cancer diagnoses during the cancer epidemic in The Netherlands.
Lancet Oncol 2020;21:750e1.Please cite this article as: Gheorghe A et al., Economic impact of avoida
pandemic: A national population-based modelling study in England, UK, E[34] Maruthappu M, Watkins J, Noor AM, et al. Economic downturns,
universal health coverage, and cancer mortality in high-income and
middle-income countries, 1990-2010: a longitudinal analysis. Lancet
(London, England) 2016;388(10045):684e95.
[35] De Angelis R, Sant M, Coleman M. Cancer survival in Europe
1999-2007 by country and age: results of EUROCARE-5 e a
population-based study. Lancet Oncol;15(1):23-34.
[36] Sun L, Legood R, dos-Santos-Silva I, Gaiha SM, Sadique Z.
Global treatment costs of breast cancer by stage: a systematic
review. PloS One 2018;13(11):e0207993.
[37] Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic
burden of cancer across the European Union: a population-based
cost analysis. Lancet Oncol 2013;14(12):1165e74.
[38] Institute for Health Metrics and Evaluation. GBD compare. 2021.
http://www.healthdata.org/data-visualization/gbd-compare.
[Accessed 13 January 2021].
[39] Fersia O, Bryant S, Nicholson R, et al. The impact of the COVID-
19 pandemic on cardiology services. Open Heart 2020;7(2):e001359.ble cancer deaths caused by diagnostic delay during the COVID-19
uropean Journal of Cancer, https://doi.org/10.1016/j.ejca.2021.04.019
